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Abstract 
 
Background: 
 
Studies have reported that pharmacologic interventions with candesartan or ramipril 
could reduce the risk of hypertension among prehypertensive subjects free of clinical 
cardiovascular disease(CVD), however, the cost-effectiveness and long-term 
cardiovascular risk of drug treatment among these population is unclear.   
Method:  
A Markov state-transition model was developed to simulate a hypothetical cohort of 
Chinese adults with high-range prehypertension (130-139/85-89 mmHg) but without 
CVD. Data on the incidence of CVD and hypertension was obtained from 
corresponding risk equations. Utility and disease-related costs were obtained from 
published literatures. Robustness and uncertainty was evaluated using deterministic 
and probabilistic sensitivity analyses. 
Results:  
Compared with placebo, drug treatment resulted in delaying the development of 
hypertension by nearly 12 years and reducing the absolute incidence of hypertension 
by 32.01% over lifetime. The cumulative incidence of coronary heart disease, stroke 
and heart failure were reduced and survival was improved from 28.46 to 28.80 years. 
The average incremental cost effectiveness ratio for drug treatment was $12,994 per 
quality-adjusted life-year and the value was mostly sensitive to the effect size of 
treatment and age starting treatment. At a willingness-to-pay threshold of >3×China 
gross domestic product per capita in 2014, there was a 30.48% chance that drug 
treatment would remain cost-effective and a low chance of being cost-effective if 
relative risk of treatment on hypertension was larger than 0.64. 
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Conclusion: Drug treatment for prehypertension may help stem the current epidemic 
of hypertension among Chinese adults free of CVD, which may in turn reduce CVD 
complications and potentially be cost effective. 
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Introduction 
 
Hypertension is the leading risk factor for cardiovascular disease (CVD) in China and 
it contributes to 2.33 million cardiovascular deaths in 2005[1]. Despite tremendous 
efforts to promote healthful lifestyles and drug treatment rate, the prevalence of 
hypertension has increased from 20% among men and 17% among women in 2002 to 
31.2% and 28.0%, respectively, in 2009[2, 3]. The term of “prehypertension” was 
introduced in Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VII) to highlight 
an at-risk population. It is believed that prehypertension is a precursor of clinical 
hypertension and successfully control this population would reduce the potential 
cardiovascular burden [4].  
Currently, the treatment of prehypertension is primarily nonpharmacological lifestyle 
changes such as healthy dietary habits, overweight/obesity control [5]. However, an 
important obstacle to the success of these strategies is that lifestyle modification 
treatments are difficult to maintain and may require large-scale social and policy 
changes as well as the patients himself [5]. The trial of preventing 
hypertension(TROPHY) study was the first trial to perform pharmacological 
intervention amongst individuals with prehypertension. Results from TROPHY 
suggested that treatment with Candesartan significantly reduced the incidence of 
hypertension, even after discontinuing drug therapy for 2 years [6]. This is in 
agreement with another clinical trial (prevention of hypertension with the angiotensin-
converting enzyme inhibitor ramipril in patients with high-normal blood 
pressure(PHARAO) study) performed in Germany [7]. In this study, Ramipril is 
proved to be effective in reducing the incidence of office hypertension by 34.4%. 
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However, there are no studies to assess whether early drug treatment of 
prehypertension can reduce its long-term cardiovascular consequences. 
Additionally, nearly 30% of the general adult population in China have 
prehypertension and the health and economic consequences caused by 
prehypertension are substantial [8-10]. It is important that an effective strategy must 
be carefully chosen on the basis of both public health and economic reasons. However, 
we are still unclear whether prescribing drugs among individuals with 
prehypertension but without clinical CVD is cost-effective, given the relatively low 
absolute risk amongst this population [11, 12]. 
The aim of our study was to combine data from published clinical trials and 
epidemiological studies to predict 1) medium and long-term hypertension incidence 
and its associated cardiovascular risk and 2) the lifetime cost-effectiveness of 
pharmacological therapy versus placebo intervention among individuals with 
prehypertension free of CVD. 
1. Method 
2.1 Model structure  
We adopted a similar approach to develop a state-transition Markov model used by 
Herman et al for the primary prevention of type 2 diabetes mellitus in adults with 
impaired glucose tolerance [13]. Our model simulated the progression from 
prehypertension to onset of hypertension, to hypertension with complications and 
death. Simultaneously, this model allowed individuals with prehypertension to move 
to CVD/death directly (Figure 1). In total, we modelled the following 10 distinct 
health states: (1) healthy with prehypertension; (2) hypertension; (3) stroke; (4) post 
stroke; (5) coronary heart disease(CHD); (6) post CHD; (7) heart failure (HF); (8) 
post HF; (9) CVD mortality and (10) non-CVD mortality. After each cycle, cohort 
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members were redistributed to one of the above ten health states. Individuals reaching 
a CVD state by the end of the first year could subsequently transit to another state 
(e.g., the occurrence of stroke after HF). Subsequent to a primary event, patients 
might move to a chronic heath state (post CHD or post HF or post stroke), which had 
a higher risk to suffer a new CVD event or death. Due to the lack of data, some states 
were not modelled (e.g., myocardial infarction after post-stroke). Subjects transiting 
to hypertension had a similar pathway as those with prehypertension, but they could 
not return to prehypertension (linear model without remission) and had a different 
pre-specified transition probability. The detailed transition pathways could be found in 
the online supplementary Figure A1 to Figure A5. 
In this study, we simulated two cohorts: one that followed individuals who received 
placebo treatment (placebo intervention) and the other one which followed individuals 
who were prescribed antihypertensive treatment (drug treatment).  This will keep 
consistence with the two completed trials[6-7] after considering the fact that no head-
to-head clinical trials were performed to compare drug treatment, intensive lifestyle 
changes and usual care. All prehypertensive individuals entered the model with their 
pre-specified characteristics and were followed along the disease paths until they 
turned 100 years old or died. The model cycle length was 1 year, and half-corrections 
were applied. A more detailed description for the base-case study population could be 
found in the online supplementary file. 
2.2 Transition probability  
The values for the transition probabilities and other inputs were mainly obtained from 
published evidences among Chinese population and summarized in Table 1. A 
prediction model for hypertension risk was used for estimating hypertension incidence 
rate [14]. The incidence of each primary CVD events (stroke, HF and CHD) was 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
8 
 
derived from their corresponding risk equations reported in studies [15-17] on the 
basis of individual data from Nanjing Community Cardiovascular Risk Survey study 
[18]. This will keep the correlation between each of the risk factors. The distribution 
for each risk factors among participants with prehypertension and hypertension could 
be found in online supplementary Table A3 and Table A4. As the age in this study 
was mainly from 30 to 75 years old, exponential interpolation was employed to 
smooth the age-specific annual rates to persons older than 75 years (online 
supplementary Figure A6 and A7). A detailed description for the estimation of 
primary CVD event rate could be found in the online supplementary file.  
Each primary event might be followed by secondary events or chronic conditions, and 
individual who experienced a first non-fatal cardiovascular event would have a higher 
risk of sequelaes. As there were no suitable risk equations to calculate the risk for 
each age/sex stratum among Chinese population, transition probabilities for 
subsequent events (within or more than 1 year after a primary event) were drawn from 
registries and/or meta-analysis studies [19-24]. These rates were varied in sensitivity 
analyses (online supplementary Table A5). However, for the sake of conservative 
estimation, the probabilities of new events in any of the post-CVD states were not 
adjusted their different blood pressure (BP) categories.  
As evidences in the published literature demonstrated that prehypertension may be 
associated with higher CVD mortality, we separated mortality into CVD and non-
CVD mortality [1, 8]. Age- and sex-specific risks of all-cause/CVD mortality were 
derived from Chinese National Statistical Office in 2013[25]. The non-CVD mortality 
risks were recalculated after exclusion of CVD death from the total mortality and this 
was assumed to be unaffected by the states in the model.  
2.3 Treatment effect  
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Antihypertensive treatment could significantly decrease the risk of CVD morbidity or 
mortality by lowering BP among patients with hypertension as well as those with 
clinical history of CVD but without hypertension [26-28]. However, trials to date 
could only indicate a deceasing risk of incident hypertension, rather than a reduction 
in CVD risk among prehypertensive individuals without prior CVD [6, 7, 11]. Our 
model only incorporated the benefits of drug treatment in hypertension incidence, and 
made the conservative assumption of no effect in CVD risk (Table 1).  
2.4 Cost  
Costs data were obtained from multiple sources, including the China Health Statistics 
Yearbook report and health economics researches (Table 1). For costs of 
prehypertension, we assumed it was the same as those with hypertension, although the 
dose for this specific population may be lower. This approach could be justifiable 
because it would lead to a conservative estimate. In our model, we used the data from 
a cost-effectiveness and an observational study [29, 30]. For costs of CVD events 
during year 1, the values were obtained from several recently published articles which 
included detailed breakdown costs (eg, drug cost, salary costs of primary healthcare 
providers) [31-34]. Cost of recurrent stroke or MI were captured by applying the same 
cost of first-year events. The costs were estimated from a health system perspective 
and were inflated to the 2014 price level using the average rate of inflation in China 
from 2009 to 2014 and converted to US dollars (6.25 Yuan≈1 USD 2014). A more 
detailed description for cost estimation could be found in the online supplementary 
file. 
2.5 Utility  
The utility measured in a 2008 survey in China was applied to individuals without 
CVD [35]. We derived utility weight of CHD, stroke or HF from a published cost-
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effectiveness study [36], as the preference weights for them were not available in 
Chinese population (Table 1). Quality-adjusted life-years (QALYs) were calculated 
by multiplying the length of time spent in a certain health state by the utility 
associated with that health state.  
2.6 Base-case analysis  
We used results from the Nanjing Community Cardiovascular Risk Survey study as a 
proxy for participants with prehypertension [18]. On average, members of the cohort 
had a mean age of 50.5 years, were 54.4% female, had a mean systolic blood 
pressure(SBP), diastolic blood pressure(DBP) and body mass index(BMI) of 
131.9mmHg, 82.4 mmHg, 24.5 kg/m
2 
, respectively. Using our base-case cohort, we 
assessed the simulated 5-year, 10-year and lifetime cumulative incidence of 
hypertension, CVD events and life expectancy by the method of Markov model cohort 
simulation. Incremental cost-effectiveness ratios (ICERs) were also calculated by 
dividing the incremental change in total healthcare costs by the incremental change in 
QALYs. The degree of cost-effectiveness was evaluated based on the WHO Choosing 
Interventions That Are Cost Effective (highly cost-effective, ICER less than the gross 
domestic product(GDP) per capita; moderately cost-effective, ICER of 1-3×GDP per 
capita; and not cost-effective, ICER of>3×GDP per capita) [37]. The gross domestic 
product(GDP) per capita of China in 2014 was reported to be $7,593.9 from the World 
Bank report [38]. Cost and utility would be both discounted at a 3% annual rate in the 
future for the primary projections. All analyses were conducted using a life-time 
horizon unless otherwise indicated. 
2.7 Analysis of uncertainty 
The impact of uncertainty in model variables on the ICER was tested by a series of 
sensitivity analyses. First, in the 1-way sensitivity analysis, each input parameter was 
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varied over a set of plausible ranges provided in Table 1 and online supplementary 
Table A5. Second, a two-way sensitivity analysis was performed to assess how large 
the changes of the first two key inputs must be in order to exceed the cost-effective 
threshold (ICER of >3×GDP per capita=$22,782). Third, in order to assess how 
sensitive the results were to variations in simultaneous changes of several variables, 
we also conducted a probabilistic sensitivity analysis (PSA). We ran our model for 
5,000 repetitions using a Monte Carlo simulation and at each simulation a value for 
each of the 54 model parameters were randomly selected based on their respective 
distributions, which were shown in Tables 1 and online supplementary Table A5. In 
our model, probabilities, prevalence rates, and preference weights were assumed to 
follow a beta distribution, and cost data were assumed to follow a gamma distribution. 
Additionally, uniform and triangular distributions were used where appropriate. The 
incremental cost-effectiveness scatter plot and acceptability curve were constructed to 
test the uncertainty of ICER from the derived 5,000 pairs of incremental cost and 
QALYs between these two strategies. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12 
 
 
2. Results  
3.1 Model validation  
The findings from our model indicated a reasonable concordance between model 
predictions and national life tables (30.20 vs. 31.31 for women, 26.69 vs. 27.21 for 
men). Our results showed that the 5-year absolute cardiovascular risk (except HF) was 
relatively low (2.58%), however, each event rate was found to be within reported 
ranges (online supplementary Tables A6). 
3.2 Base-case analysis  
Using baseline estimates, our model simulated the lifetime cumulative incidence of 
hypertension, which was shown in online supplementary Tables A8. The figure 
indicated that approximately 30% of individuals with placebo would develop 
hypertension within 5 years, however, it would take more than 17 years to achieve 
that percent for those prescribed antihypertensive medication. Thus, compared to 
placebo, the drug intervention delayed the onset of hypertension by about 12 years. 
Over a lifetime, prescribing drugs among individuals with prehypertension would 
reduce the risk for developing hypertension by 32.01% (Table 2).  
Table 2 summarizes the potential changes in CVD events and life expectancy as well 
as costs, which may be caused by the delaying or reduction of hypertension risk. In 
general, risk reductions in CHD, stroke and HF were observed for all different time 
horizons. The reduction in mortality or clinical event risk from drug treatment 
increased life expectancy by 0.34 years and QALYs by 0.22 (undiscounted: 0.09), 
whereas it increased discounted costs from $3,690.1 to $4,859.5 (an increment of 
$1,169.4). Therefore, based on the WHO criteria, the discounted lifetime ICERs 
might be moderately cost-effective ($12,994 per QALY within ICER of 1-3×GDP per 
capita). 
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3.3 Uncertainty analysis 
Our cost-effectiveness analysis was relatively insensitive to a variety of alternative 
assumptions (online supplementary Figure A9), specifically for those relating to 
secondary CVD events. The 10 individual parameters that were most influential in 
ICER estimates. were RR of hypertension on treatment, age starting treatment, BMI, 
drug treatment costs, discount rate, SBP, utility of stroke, incidence of stroke among 
hypertensive persons, utility of non-CVD state, and DBP.  
A two-way sensitivity analysis was performed to investigate the relationship of the 
two most influential variables (RR of hypertension on treatment and age starting 
treatment). At a willingness-to-pay threshold of $22,870 per additional QALY (3 
times the GDP), our model indicated that the probability of being cost-effective 
increased with age and decreased with the higher RR of hypertension on treatment, 
but there was low probability if the RR of treatment was larger than 0.64 (online 
supplementary Figure A10). 
To further reflect the uncertainty in the estimates, the incremental cost-effectiveness 
scatter plot was derived from PSA (online supplementary Figure A11). In 
comparison with placebo, prescribing drug to participants with prehypertension would 
result in an increase in QALYs in 99.70% of simulations. Regarding the incremental 
costs, drug treatment for prehypertension would decrease costs in 5.87% of 
simulations. Overall, the cost-effectiveness for drug treatment was 30.48% with a 
maximum willingness to pay to be $22,870 per additional QALYs. Also, we found an 
increasing probability of being cost-effective if the decision maker was willing to pay 
more for an additional health gain, and a 5.80% of the probability that drug 
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intervention was cost-saving (Figure 2).  
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3. Discussion: 
This study provides evidence that drug treatment with the angiotensin-converting 
enzyme inhibitor ramipril or the angiotensin receptor antagonist candesartan for 
prehypertension, as compared with placebo intervention, could delay and/or prevent 
hypertension by approximately 12 years over a lifetime, which would result in a 
reduction in cardiovascular complications and an increase in life expectancy. In 
addition, when patients’ preferences and cost of treatment were both taken into 
account, we found that prescribing drugs among prehypertension was moderately 
cost-effective, costing $12,994 per QALY. 
In comparison with other currently accepted medical interventions for hypertension or 
CVD, our study found a relative smaller life-year or CVD gains from our base-case 
model [36, 39-42]. For example, our models projected that an antihypertensive 
intervention would prolong life expectancy of prehypertensive individuals by 0.34 
years. By contrast, Tsevat et al [39] predicted that BP control could increase gains in 
life expectancy of 2.3 and 1.7 years in men and women, respectively. Geisler et al [36] 
estimated that renal denervation substantially increased median survival from 17.1 
years to 18.4 years and reduced cardiovascular mortality by 30% and all-cause 
mortality by 15%. We also found a comparable benefit showing metformin 
interventions could only improve survival by 0.2 years among drug therapy in adults 
with impaired glucose tolerance [13]. We believed that the relative smaller benefits in 
our study may be ascribed to the relatively low absolute risk of CVD for this specific 
population (prehypertension but without CVD) and assumption of no effect on CVD 
incidence by drug treatment.  
In general, the overall conclusions of the cost-effectiveness analysis for our study 
were robust to the ranges of uncertainty surrounding utility weights, and costs as well 
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as treatment effect. Although it seemed that the judgment of cost-effectiveness was 
most sensitivity to the RR of antihypertensive treatment, it was still important that 
health policy should be based on what is determined to be an acceptable ICER. The 
acceptable ICER from our relative low CVD risk population (2.58% of 5-year CVD 
risk) may support the concept of using predicted baseline CVD risk equations to guide 
blood pressure-lowering treatment decisions, not just the BP levels [26, 43, 44]. This 
is because prehypertensive subjects often exhibited several additional risk factors (e.g., 
dyslipidemia, obesity) and could have the same absolute CVD risk with those with 
hypertension [10, 12]. The idea of implementing intensive BP control in high-risk 
patients was confirmed by SPRINT trial, which may partly support our study results.   
Several limitations need to be acknowledged in our study. First, due to the lack of 
evidences to show the benefits on CVD risk by drug treatment among  
prehypertensive subjects without CVD, our model only captured the benefit of 
hypertension risk and assumed no direct benefits on stroke, CHD, and HF. This 
limitation might underestimate the benefit and result in conservative estimates. 
Second, we did not incorporate the rate of drug side effects and their associated costs 
in our model, however, it is anticipated to have little influence on the final evaluation 
as both studies reported a comparable and low rate of serious adverse events between 
groups and no concerns were raised for adverse reactions caused by drug [6, 7]. Third, 
as there are no reports discussing the medication compliance of a life-long drug 
treatment among these healthy prehypertensive adults, a potential impact on our result 
may deserve more attentions. Fourth, many key inputs into the model were derived 
from Chinese population and we did not know whether our results were transferable 
to other countries, especially considering the large variations in costs from different 
countries. Finally, as all computer simulation studies, we were clear that average gains 
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in life expectancy or ICER from the prediction models may not apply to the individual 
patient, and therefore results need to be interpreted with caution.  
In summary, our model projected that drug treatment in prehypertensive Chinese 
adults free of CVD could delay and/or prevent onset of hypertension and its 
complications. This policy may be cost-effective and reasonable, but are highly 
dependent on the treatment effectiveness.  
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Figure titles and legends:  
Figure 1: Schematic Depiction of the Model 
              Hypertension module;              prehypertension module;                MI module;              
HF module;             Stroke module 
Figure 2: Cost-effectiveness acceptability curve 
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Table 1 key model parameters 
Data input  Base Case Numeric Value (Range) or Survival Model (Covariates) Distribution  Reference  
Age 50.5 (30-80)years Triangular [18] 
Sex 54.4(0-100)% female  Beta [18] 
BMI 24.5(20-30)kg/m
2
 Normal  [18] 
SBP 131.9(120-139)mmHg Triangular [18] 
DBP 82.4(65-89)mmHg Triangular [18] 
Hypertension incidence Weibull(age, sex, BMI, SBP, DBP) ±25% uniform [14] 
CHD incidence  Exponential (age, sex, DBP, SBP,TC, HDL, DM, Smoking)  ±25% uniform [16] 
Stroke incidence  Exponential (age, sex, DBP, SBP, FHS, AF, DM)  ±25% uniform [17] 
HF incidence Exponential (age, sex, SBP, DM, LVH, BMI, heart rate, CHD, valve disease) ±25% uniform [15] 
All-cause mortality Age and sex dependent  ±25% uniform [25] 
Stroke mortality First year: 12.3% for male, 17.8% for female; beyond: SMR 2.23(1.29–3.88) on background 
mortality 
Beta/ 
Lognormal 
[19-21] 
CHD mortality First year: 5.7%; beyond: SMR 1.43(1.18–1.72) on background mortality Beta/ 
Lognormal 
[20, 22] 
HF mortality First year: 15.9%; beyond: 8% Beta [23, 24] 
Effect of treatment     
RR of hypertension on treatment 0.34(0.25-0.95) Triangular [6, 7] 
Cost     
Annual cost for Antihypertensive 
treatment 
$161.44($53.76-$484.32) Gamma [29, 30] 
Annual cost for Stroke $3358.11($1,118.88-$10,074.24) first year, post $1,315.16($438.24-$3,945.44) Gamma [25, 31, 
32] 
Annual cost for CHD $4,820.89($1,606.88-$14,462.56) first year, post $382.08($160.64-$1,446.24) Gamma [25, 33] 
Annual cost for HF $1,260.16($420-$3,780.48) first year, post $293.92($97.92-$881.76) Gamma  [25, 34] 
Quality of life weights(utilities)    
No cardiovascular disease Age and sex dependent  ±25% uniform [35] 
Stroke 0.63 (0.26 to 0.92) Beta [36] 
CHD First year: 0.76 (0.5 to 0.87); beyond: 0.88 (0.67 to 0.94) Beta [36] 
HF 0.71 (0.43 to 0.84) Beta [36] 
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Discount rate 3% (0%-5%) Uniform Assumed  
 
AF: atrial fibrillation; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DM: diabetes mellitus; TC: total cholesterol; HDL: high-
density lipoprotein; FHS: family history stroke; HF: heart failure; LVH: left ventricular hypertrophy; CHD; coronary heart disease; RR: relative risk 
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Table 2  Base-Case Results 
 
5-year time horizon  
 
10-year time horizon   
 
lifetime horizon  
Outcomes  
Placebo 
Intervention 
Drug 
Treatment RD RR   
Placebo 
Intervention 
Drug 
treatment RD RR   
Placebo 
Intervention 
Drug 
treatment RD RR 
Hypertension 31.37 11.80 19.57 0.38  
 
51.17 20.85 30.32 0.41  
 
80.66 48.65 32.01 0.60  
CHD,% 0.80 0.79 -0.01 0.99  
 
1.83 1.73 -0.10 0.95  
 
12.53 12.30 -0.23 0.98  
Stroke,% 1.46 1.42 -0.04 0.97  
 
3.49 3.21 -0.28 0.92  
 
26.89 25.41 -1.48 0.94  
HF,% 0.95 0.90 -0.05 0.95  
 
2.22 2.00 -0.22 0.90  
 
12.82 12.65 -0.17 0.99  
CV mortality,% 0.59 0.57 -0.02 0.97  
 
1.64 1.53 -0.11 0.93  
 
22.96 22.56 -0.40 0.98  
All-cause mortality,% 3.08 3.06 -0.02 0.99  
 
7.31 7.19 -0.12 0.98  
     Life years 
          
28.46 28.80 0.34 
 Undiscounted QALYs 
          
20.43 20.65 0.22 
 QALYs discounted,3% 
          
13.46 13.55 0.09 
 Cost discounted($),3% 
          
3690.1 4859.5 1169.4 
 Discounted ICER                     $12,994/QALY 
CHD; coronary heart disease; HF: Heart failure; QALYs: quality adjusted life years; ICER: incremental cost-effectiveness ratio; RD: risk difference; RR: relative risk  
